182 related articles for article (PubMed ID: 30561903)
1. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry.
Salvatore D; Padoan R; Buzzetti R; Amato A; Giordani B; Ferrari G; Majo F
Pediatr Pulmonol; 2019 Feb; 54(2):150-157. PubMed ID: 30561903
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis with non-G551D gating mutations in Italy: Epidemiology and clinical characteristics.
Salvatore D; Carnovale V; Majo F; Padoan R; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
Pediatr Pulmonol; 2021 Feb; 56(2):442-449. PubMed ID: 33219628
[TBL] [Abstract][Full Text] [Related]
3. [Italian Cystic Fibrosis Registry (ICFR). Report 2021-2022].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2024; 48(2 Suppl 2):1-41. PubMed ID: 38742380
[TBL] [Abstract][Full Text] [Related]
4. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2021; 45(3 Suppl 1):1-37. PubMed ID: 34132083
[TBL] [Abstract][Full Text] [Related]
5. [Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
Giordani B; Amato A; Majo F; Ferrari G; Quattrucci S; Minicucci L; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2019; 43(4S1):1-36. PubMed ID: 31370382
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
7. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
[TBL] [Abstract][Full Text] [Related]
8. Clinical phenotype of cystic fibrosis patients with the G551D mutation.
Comer DM; Ennis M; McDowell C; Beattie D; Rendall J; Hall V; Elborn JS
QJM; 2009 Nov; 102(11):793-8. PubMed ID: 19734299
[TBL] [Abstract][Full Text] [Related]
9. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
[TBL] [Abstract][Full Text] [Related]
12. Clinical Presentation of the c.3844T>C (p.Trp1282Arg, W1282R) Variant in Russian Cystic Fibrosis Patients.
Petrova NV; Kashirskaya NY; Krasovskiy SA; Amelina EL; Kondratyeva EI; Marakhonov AV; Vasilyeva TA; Voronkova AY; Sherman VD; Ginter EK; Kutsev SI; Zinchenko RA
Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 32992607
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.
Schippa S; Iebba V; Santangelo F; Gagliardi A; De Biase RV; Stamato A; Bertasi S; Lucarelli M; Conte MP; Quattrucci S
PLoS One; 2013; 8(4):e61176. PubMed ID: 23613805
[TBL] [Abstract][Full Text] [Related]
14. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation.
Sawicki GS; Konstan MW; McKone EF; Moss RB; Lubarsky B; Suthoff E; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan WJ; Duncan ME; Yang Y
Pulm Ther; 2022 Dec; 8(4):385-395. PubMed ID: 36319933
[TBL] [Abstract][Full Text] [Related]
15. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2022; 46(4 Suppl 2):1-38. PubMed ID: 36102313
[TBL] [Abstract][Full Text] [Related]
16. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
Padoan R; Bassotti A; Seia M; Corbetta C
Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
Dupuis A; Keenan K; Ooi CY; Dorfman R; Sontag MK; Naehrlich L; Castellani C; Strug LJ; Rommens JM; Gonska T
Genet Med; 2016 Apr; 18(4):333-40. PubMed ID: 26087176
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
